Galenic formulations of organic compounds

A solid oral dosage form comprising about 300 mg aliskiren free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC0-96 of aliskiren ranging from about 1480 to about 1859 ng·h/mL following administration of a single dosage of said dosage form.

A solid oral dosage form comprising about 300 mg of aliskiren free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of aliskiren ranging from about 186 to about 394 ng/mL between about 0.25 and 6 hours following administration of a single dosage of said dosage form, whereby an arithmetic mean AUC0-96 of aliskiren ranges from about 1480 to about 1859 ng·h/mL.

A solid oral dosage form comprising about 300 mg of aliskiren free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of aliskiren ranging from about 261 to about 425 ng/mL between about 0.5 and about 6 hours following repeated administration of said dosage form every 24 hours through steady state conditions.

A solid oral dosage form comprising about 300 mg aliskiren free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC0-τ of aliskiren ranging from about 1671 about 2519 ng·h/mL following repeated administration of said dosage form every 24 hours through steady state conditions.

A solid oral dosage form comprising about 300 mg of aliskiren free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of aliskiren ranging from about 261 to about 425 ng/mL between about 0.5 and 6 hours following repeated administration of said dosage form every 24 hours through steady state conditions, whereby an arithmetic mean AUC0-τ of aliskiren ranges from about 1671 to about 2519 ng·h/mL.

A method for the treatment of conditions mediated by renin activity, which method comprises administering a solid oral dosage form comprising about 300 mg of aliskiren free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of aliskiren ranging from about 186 to about 394 ng/mL between about 0.25 and about 6 hours following administration of a single dosage of said dosage form.

A method for the treatment of conditions mediated by renin activity, which method comprises administering a solid oral dosage form comprising about 300 mg aliskiren free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC0-96 of aliskiren ranging from about 1480 to about 1859 ng·h/mL following administration of a single dosage of said dosage form.

A method for the treatment of conditions mediated by renin activity, which method comprises administering a solid oral dosage form comprising about 300 mg of aliskiren free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of aliskiren ranging from about 186 to about 394 ng/mL between about 0.25 and 6 hours following administration of a single dosage of said dosage form, whereby an arithmetic mean AUC0-96 of aliskiren ranges from about 1480 to about 1859 ng·h/mL.

A method for the treatment of conditions mediated by renin activity, which method comprises administering a solid oral dosage form comprising about 300 mg of aliskiren free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of aliskiren ranging from about 261 to about 425 ng/mL between about 0.5 and about 6 hours following repeated administration of said dosage form every 24 hours through steady state conditions.

A method for the treatment of conditions mediated by renin activity, which method comprises administering a solid oral dosage form comprising about 300 mg aliskiren free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean AUC0-τ of aliskiren ranging from about 1671 about 2519 ng·h/mL following repeated administration of said dosage form every 24 hours through steady state conditions.

A method for the treatment of conditions mediated by renin activity, which method comprises administering a solid oral dosage form comprising about 300 mg of aliskiren free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean maximum plasma concentration of aliskiren ranging from about 261 to about 425 ng/mL between about 0.5 and 6 hours following repeated administration of said dosage form every 24 hours through steady state conditions, whereby an arithmetic mean AUC0-τ of aliskiren ranges from about 1671 to about 2519 ng·h/mL.